Table 3.
Prevalence and odds ratio of Crohn’s disease outcomes in China vs the United States
| Outcome | China (n = 49) | United States (n = 145) | Unadjusted OR (95%CI), P value (Reference = US) | Adjusted1 OR (95%CI), P value (Reference = US) |
| Ileal involvement | 63.3% | 63.5% | 0.99 (0.50-1.94) | 1.14 (0.51-2.55) |
| P = 0.98 | P = 0.74 | |||
| Surgery for IBD | 51.0% | 49.7% | 1.06 (0.55-2.02) | 1.70 (0.77-3.75) |
| P = 0.87 | P = 0.19 | |||
| Ever steroids use | 46.9% | 91.0% | 0.09 (0.04-0.19) | 0.19 (0.07-0.50) |
| P < 0.0001 | P = 0.0007 | |||
| Steroids use within 3 mo of diagnosis | 24.5% | 46.2% | 0.38 (0.18-0.78) | 0.53 (0.22-1.25) |
| P = 0.009 | P = 0.15 | |||
| Ever immunomodulators2 | 73.5% | 61.4% | 1.74 (0.85-3.57) | 2.13 (0.92-4.91) |
| (n = 36) | (n = 89) | P = 0.13 | P = 0.08 | |
| 6-MP/Azathioprine | 88.9% | 89.9% | ||
| Methotrexate | 19.4% | 23.6% | ||
| Cyclosporine | 0% | 6.7% | ||
| Tacrolimus | 0% | 3.4% | ||
| Ever biologics use | 34.7% | 73.8% | 0.19 (0.09-0.38) | 0.09 (0.04-0.24) |
| P < 0.0001 | P < 0.0001 | |||
| Ever TPN use | 8.2% | 21.4% | 0.33 (0.11-0.98) | 0.67 (0.19-2.38) |
| P = 0.05 | P = 0.54 | |||
| Antibiotics use within 30 d before time of survey | 18.8% | 15.9% | 1.22 (0.52-2.87) | 1.29 (0.47-3.55) |
| P = 0.64 | P = 0.62 |
1
Adjusted for sex, smoking status at diagnosis, age at diagnosis older than 40 years or less, and duration of disease at survey completion;
2
For ever users of immunomodulators, the percentage of use of each type of immunomodulators was calculated. IBD: Inflammatory bowel disease; 6-MP: Mercaptopurine; TPN: Total parenteral nutrition; OR: Odds ratio.